Schizophrenia Research
Volume 113, Issue 2 , Pages 138-144 , September 2009

A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia

  • Rachel Miller

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY, 11004, United States
    • Permanent addresses: National Institute of Mental Health, 10 Center Dr., Bldg. 10, Bethesda, MD 20892-1600, United States.
    • Corresponding Author InformationCorresponding author. National Institute of Mental Health, 10 Center Drive, Bldg. 10, Room 3B24, Bethesda, MD 20892-1600, United States. Tel.: +1 301 496 7962; fax: +1 301 402 0296.
    • ,
  • Geoffrey Ream

      Affiliations

    • Adelphi University, 1 South Avenue, Garden City, NY 11530, United States
    • ,
  • Joanne McCormack

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY, 11004, United States
    • ,
  • Handan Gunduz-Bruce

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY, 11004, United States
    • Permanent addresses: Yale University School of Medicine, 300 George St., New Haven CT 06511, United States.
    • ,
  • Serge Sevy

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY, 11004, United States
    • ,
  • Delbert Robinson

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY, 11004, United States

Received 26 November 2008 ,Revised 13 April 2009 ,Accepted 14 April 2009.

References 

  1. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatr. Rehabil. J. 2001;25(1):60–67
  2. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry. 1998;172(33):53–59
  3. Bottlender R, Sato T, Jager M, Groll C, Strauss A, Moller HJ. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenia and schizoaffective patients. Eur. Arch. Psychiatry Clin. Neurosci. 2002;252:226–231
  4. Buhler B, Hambrecht M, Loffler W, Heiden W, Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse—a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002;54:243–251
  5. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta. Psychiatr. Scand. 2002;106:286–290
  6. Drake RE, Osher FC, Noordsy DL, Teague GB, Hurlbut SC, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 1990;16:57–67
  7. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, Version 2.0, 8/98 revision). New York: Biometrics Research Department; 1998;
  8. Gaebel W, Janner M, Frommana N, Pietzcker A, Kopcke W, Linden M, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 2002;53:145–159
  9. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O 'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr. Psychiatry. 1998;39(4):215–219
  10. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick , et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004;66:125–135
  11. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry. 2000;34(3):468–475
  12. Hollingshead AB, Reidlich FC. Social Class and Mental Illness: A Community Study. New York: Wiley; 1958;
  13. Kamali M, Kelly BD, Clark M, Browne S, Gervin M, Kinsella A, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur. Psychiatr. 2006;21:29–33
  14. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry. 2002;63:892–909
  15. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. Br. J. Psychiatry. 1998;172:45–52
  16. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. Substance abuse in first-episode non-affective psychosis. Schizophr. Res. 2006;88:55–62
  17. Linden M, Godemann F, Gaebel W, Kopke W, Muller P, Muller-Spahn F, et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophr. Bull. 2001;27(4):585–596
  18. Linszen DH, Dingermans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry. 1994;51:273–279
  19. Linszen DH, Dingermans PM, Lenior ME. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr. Res. 2001;51:55–61
  20. Miller R, McCormack Caponi J, Sevy S, Robinson D. The insight–adherence–abstinence triad: an integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bull. Menninger. Clin. 2005;69:220–236
  21. Mojtabai R, Lavelle J, Gibson PJ, Sohler NL, Craig TJ, Carlson GA, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr. Serv. 2002;53(3):337–339
  22. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: west London first episode schizophrenia study. Acta. Psychiatr. Scand. 2003;108:439–446
  23. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur. Psychiatr. 2002;17(3):148–154
  24. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann. Pharmacother. 2003;37:625–630
  25. Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, Peters EN, et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend. 2005;79(2):211–223
  26. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic edpisode. Schizophr. Res. 2006;83:53–63
  27. Ream GL, Benoit E, Johnson BD, Dunlap E. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend. 2008;95:199–208
  28. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitmen B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999;156:544–549
  29. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002;57:209–219
  30. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry. 2006;163:2096–2102
  31. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia—Change Version. 3rd ed.. New York State Psychiatric Institute; 1978;
  32. Svedberg B, Mesterton A, Cullberg . First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc. Psychiatry Psychiatr. Epidemiol. 2001;36(7):322–337
  33. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39:69–72
  34. Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta. Psychiatr. Scand. 2000;102:203–210
  35. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr. Res. 2006;81:145–150
  36. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int. J. Qual. Health Care. 2007;19:134–140

PII: S0920-9964(09)00178-9

doi: 10.1016/j.schres.2009.04.018

Schizophrenia Research
Volume 113, Issue 2 , Pages 138-144 , September 2009

Article Tools

* Image Usage & Resolution